A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

NCT03980002 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: FCR and Ibrutinib
DRUG: BR and Ibrutinib
DRUG: Ibrutinib and Thalidomide

Sponsor

Institute of Hematology & Blood Diseases Hospital, China